



PharmAust
LIMITED

Pitt Street Research Life Sciences Conference
28 November 2019

ASX: PAA

ACN 094 006 023

Corporate Structure



Epichem Synthetic Medicinal Chemistry
Expected 2019-2020 sales A\$ 4.2m+

Pitney Pharmaceuticals: “repurposing” a registered drug (Monepantel) in oncology

Corporate Snapshot

ASX Code:	PAA
Market Cap at \$0.11	\$35M
Cash (at 25 November 2019)	\$3.2M
Debt (EFIC)	\$325K
Epichem Revenue Forecast 2019-2020	\$4.2M

Total Shares on Issue	301,814,647
Options (Unlisted)	56,801,956
Top 20 Own	35%
Board/Exec Own	9.3%



Experienced Board & Management Team

Dr. Roger Aston, Executive Chairman

- > 30 years experience in the pharmaceutical and healthcare industries.
- Director or chairman on a number of boards carrying out late stage drug development.

Robert Bishop, Executive Director

- > 30 years experience in corporate finance and equity capital markets
- Lawyer and an investment banker.

Neville Bassett, Non-Executive Director

- Member of the Order of Australia (AM)
- > 35 years working in accounting, finance and stockbroking

Sam Wright, Director & Company Secretary

- > 20 years experience in biotech and healthcare.
- Extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, corporate governance, statutory financial reporting, and shareholder relations.

Dr. Richard Mollard, Chief Scientific Officer

- Director or chairman on a number of boards carrying out late stage drug development.
- Extensive national and international experience

Colin La Galia, Epichem Chief Executive Officer

- > 30 years experience in the pharmaceutical and healthcare industries.
- Director or chairman on a number of boards carrying out late stage drug development.

PharmAust Background

- Lead product is **Monepantel** (MPL) – a repurposed drug already approved for Veterinary use by Elanco Animal Health (US \$10.7b)
- PharmAust **patented MPL** as an **anti-cancer drug** (mTOR pathway)
- **Clinical strategy** targeting **MPL** for **vet and human** applications
- **Epichem**: profitable business, forecast revenues of \$4.2m in FY2019/20
- **Option Agreement** with **Elanco US Inc** for veterinary cancer applications



Elanco Animal Health – Option Agreement



- Elanco Animal Health (NYSE:ELAN) – **MC=\$10.7B US**
- **Monepantel** compound is owned by **Elanco**, approved for the treatment of parasitic infections in sheep (patent protection to 2024)
- **Option Agreement** with Elanco to exclusive, worldwide **royalty bearing** license to commercialise MPL for treatment of **Cancer in Animals**
- **Commercial Outcome** would allow PharmAust to focus on **Human Cancer** market

Product Areas of Focus

ELANCO IS AN ESTABLISHED LEADER WITH FLAGSHIP BRANDS AND A GLOBAL PRESENCE.


They're focused on investing and innovating in the animal health priorities that mean the most to their customers and the animals in their care.



**Companion
Animal Disease
Prevention**



**Companion Animal
Therapeutics**



**Food Animal
Future Protein
& Health**



**Ruminants
& Swine**



Monepantel (MPL) In Oncology

A UNIQUE ANTI-CANCER PARADIGM

- AVAILABILITY OF GMP QUALITY DRUG
- **ELANCO PROVIDES DRUG**

MANUFACTURE
IN PLACE
THROUGH
PARTNER

ALLOWS HIGH
DOSE THERAPY

- **VERY LOW TOXICITY ON NORMAL CELLS**
- mTOR REGULATOR

- ALREADY REGISTERED AS A VETERINARY MEDICINE
- **SIMPLER PATH TO REGISTRATION**

ACCESS TO
REGISTRATION
DOSSIER FOR
SAFETY,
TOXICOLOGY

VALIDATION IN
VARIOUS
CANCER
MODELS

- MICE, CANINES AND MAN: EXTENSIVE EVALUATIONS
- **PROGRESSION FREE SURVIVAL**

Comparatives: MPL And Chemotherapy (USD 52 billion)

**THE SINGLE MOST IMPORTANT LIMITATION OF CHEMOTHERAPY
IS DOSE LIMITING TOXICITY**

ACTIVITY	MPL	CHEMOTHERAPY
PROGRESSION FREE SURVIVAL	++++	++
IMMUNOSUPPRESSION	+	++++
HIGH DOSE TOXICITY	+	+++++
RESISTANCE	?	++++
REGRESSION	++	+++++

>\$2 Billion market for approved mTOR Drugs

THE MORE IMPORTANT LIMITATIONS OF mTOR DRUGS ARE SIDE EFFECTS AND RESISTANCE

Drug	Company	Approved Indications	2018 Sales (USD million)	Side effects
Sirolimus (rapamycin)	Pfizer	Transplantation	> 1000 (?)	Infections Nausea Weakness Diarrhea Fever, Rash Swelling Cough Vomiting Itching Chest Pain Headache
Torisel (temsirolimus)		Transplantation Renal cell carcinoma Mantle Cell Lymphoma		
Afinitor (everolimus)	Novartis	Transplantation Renal cell carcinoma Breast Cancer NET (Gut, lung pancreas) TSC	> 1600	

<https://www.novartis.com/investors/financial-data/product-sales>; Rocco Monto, 2018

Initial Market - Pets and Cancer

- 6 million dogs diagnosed with cancer annually in the US
- Significant **unmet need** for **new** oncology drugs (US\$500m - USD\$1b market = 25% of market)
- **Side effects** associated with products and treatments are **limiting market growth** (Monepantel comparatively has **minor side effects and no toxicity**)
- Vet **therapeutic market** dominated by **repurposed drugs** already approved for use in humans and/or animals (= **monepantel**)
- Pet Insurance now commonplace: wtp = \$2 - \$5k/ treatment¹
- Canines are a close reflection of human outcomes with MPL

US Dog Population¹



> 90m

1. http://www.americanpetproducts.org/press_industrytrends.asp

Phase II Trial in Canines

TARGETTING B CELL LYMPHOMA IN PET OWNERS' DOGS



- **Despite poor taste** and **low dose**, past trial in B cell lymphoma demonstrated **successful outcome** (14 days, 6/7 stable disease and reductions in tumour sizes)
- **Untreated**, dogs get sicker and 50% mortality at **30 days** (range: 1 – 124 days). Current rescue protocol response rates are between 30 and 72% with a range of 1 to 5 months.
- Developed a **new tablet**: micronized, **no palatability issue**, **high dose**, **no toxicity**
- **Matched dosing and safety** with Elanco safety dossier: high short term and low long-term doses identified
- **Revisit** pet dogs with B cell lymphoma, but **with new tablet** in a **28-day trial**: continue **long term** for 3, 6 and 12+ months: **four referral sites** around Australia

PharmAust – Current Status and Next Steps

- Successful **\$2.0m** Rights Issue to **existing shareholders** completed in **April 2019**
- **Oversubscribed** placement primarily to Australian and Singaporean **fund management institutions** raises **\$2.4m** in **October 2019**
- **Sufficient funds** to complete **Phase II in dogs** as well as **progression of the human trial**, including further development of formulation & manufacture of additional tablets
- **Phase II trial** on dogs with lymphoma – **commenced Sep 2019** at the University of Melbourne's U-Vet Werribee Animal Hospital
- **Elanco Option Agreement** covers veterinary uses only
- Canine success would open the door to **human use - > USD 52 billion market**
- **Epichem** – new CEO and state of the art laboratories a key to **further growth** and **profitability**



“PharmAust is harnessing drugs targeting novel mechanisms to control cancer”



Disclaimer

This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.